<p><b>Copyright information:</b></p><p>Taken from "Inducible nitric oxide synthase, , does not mediate optic neuropathy and retinopathy in the DBA/2J glaucoma model"</p><p>http://www.biomedcentral.com/1471-2202/8/108</p><p>BMC Neuroscience 2007;8():108-108.</p><p>Published online 19 Dec 2007</p><p>PMCID:PMC2211487.</p><p></p> eyes examined; control 11.8 ± 0.2, 19; Ag-treated 11.7 ± 0.2, 23; P = 0.76). Ag-treatment did not affect the ocular hypertension during the key window in disease progression, between 10 and 11 months (control, 18.2 ± 1.0, 31; Ag-treatment, 16.6 ± 1.3, 30; P = 0.334). () Ag-treatment from 5 months of age does not alter glaucomatous neurodegeneration (given as total number analyzed, treatment group, number of that treatment with mild, moderate, severe glaucoma) 10 months, 51 controls, 22,6,23; 51 Ag-treated 21,6,25; P = 0.293; 11.5 months, 55 controls, 18,6,31; 46 Ag-treated, 16,7,23, P = 0.896. (C) Ag-treatment beginning at 3 months of age does not protect from glaucomatous neurodegeneration. Nine months old treated mice actually tended to have more severe damage (given as total number analyzed, treatment group, number of that treatment with mild, moderate, severe glaucoma) 9 months, 42 controls, 27,7,8; 41 Ag-treated 17,6,18; P = 0.04; 10 months, 43 controls, 10,1,32; 49 Ag-treated, 6,2,41, P = 0.4; 11 months, 43 controls, 4,3,36; 37 Ag-treated, 5,3,29, P = 0.8. The experiments shown in B and C were performed at different institutions (see text)
